Cancer drugs conferring low or no therapeutic benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022.

An investigator reported updated findings from the phase 2/3 study QUILT 3.032 using a July 15, 2024 data cutoff.

BOND-003 evaluated the efficacy and safety of cretostimogene grenadenorepvec, an oncolytic immunotherapy, in patients with carcinoma in situ BCG-unresponsive NMIBC.

Data on the efficacy of radical prostatectomy in managing clinically node-positive prostate cancer have been limited.

Recurrence in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer is common, and there have been a lack of alternative treatments to TURBT.

The ongoing phase 2b SunRISe-1 study is assessing TAR-200 intravesical gemcitabine delivery in patients with BCG-unresponsive high-risk NMIBC.

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Fibrate therapy may lower the risks of mortality and progression to end-stage kidney disease (ESKD), despite raising the risk for new onset stage 3 or higher chronic kidney disease (CKD), a new study ...

There may be “substantial delays” between when a drug is granted accelerated approval for a cancer indication, when negative trial results are released, and when the accelerated approval of the drug ...

(HealthDay News) — The prevalence of depression among adolescents and adults aged 12 years and older during August 2021 to August 2023 was 13.1 percent, a 60 percent increase from 2013-2014, according ...

The FDA warning is about a topical spray version of finasteride, a drug often sold online by telehealth companies like Hims, Keeps and Ro, The Wall Street Journal reported. While the pill form of ...

Prevalence of smoking continued to drop during pandemic, but prevalence of excess body weight, HPV vaccination remained stable.